Companion Diagnostic Tests in Oncology Market

Companion Diagnostic Tests in Oncology Market (Detection Technique: Protein Detection, DNA Detection, and Others; and Biomarker: EGFR, KRAS, HER2, BRAF V600E, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

Companion Diagnostic Tests in Oncology Market Outlook 2034

  • The global industry was valued at US$ 6.1 Bn in 2023
  • It is expected to grow at a CAGR of 9.5% from 2024 to 2034 and reach US$ 17.0 Bn by the end of 2034

Analyst Viewpoint

Increase in demand for targeted medicines is propelling the companion diagnostic tests in oncology market size. Companion diagnostics play a significant role in the development of targeted drugs for cancer treatment.

Integration of Artificial Intelligence (AI) in companion diagnostics is boosting the companion diagnostic tests in oncology market trajectory. The combined use of AI and companion diagnostics can help increase patient access to targeted treatments.

Key players operating in the global companion diagnostic tests in oncology market are exploring the potential of genomics to offer quick and precise detection of cancer through non-invasive blood tests.

Market Introduction

Oncology companion diagnostics is used to match a patient to a specific therapy or drug. In other words, it helps to determine if a patient should be the receptor of a drug or not. Companion diagnostics can monitor response to treatment with a particular therapeutic product. This aids in adjusting treatment to achieve improved safety or effectiveness.

Advancements in genomics and genetic sequencing are major companion diagnostic tests in oncology market trends. Next-generation Sequencing (NGS)-based companion diagnostic tests unlock the molecular information from every patient’s tumor genome to provide guidelines regarding treatment decisions for.

Personalized medicine and companion diagnostics go hand-in-hand. Companion diagnostics help decide which treatments to offer patients and which dosage to give, tailored specifically to the patient. However, the cost of personalized immunotherapies is quite high. For instance, Novartis’ KYMRIAH (approved CAR T-cell treatment) alone costs from US$ 373,000 to US$ 475,000. Hence, high cost of personalized immunotherapies is likely to limit the companion diagnostic tests in oncology market growth in the near future.

Attribute Detail
Market Drivers
  • Increase in Demand for Targeted Medicines
  • Integration of Artificial Intelligence (AI) in Companion Diagnostics

Increase in Demand for Targeted Medicines Propelling Companion Diagnostic Tests in Oncology Market Revenue

In-depth understanding of biomarkers or genetic characteristics of an individual can help customized treatment strategies. Biopharmaceutical and pharmaceutical companies are implementing several patient-centric diagnostic frameworks at the initial stages of drug development to provide targeted therapies. This, in turn, is boosting the demand for companion diagnosis, thereby fueling the companion diagnostic tests in oncology market dynamics.

Extensive research is conducted to devise targeted therapies for treating cancerous diseases such as Kaposi’s cancer, liver cancer, multiple myeloma, ovarian cancer, metastatic breast cancer, pancreatic cancer, advanced colorectal cancer, and non-small cell lung cancer. Disadvantages of chemotherapy, such as damage caused to healthy cells, are prompting the use of cancer biomarker testing, precision medicine in oncology, and molecular diagnostic tests for cancer. This is projected to drive the market development in the next few years.

As per the World Cancer Research Fund International, the year 2020 alone witnessed 18.1 million cancer cases. Rise in prevalence of cancer and surge in need for targeted therapy are contributing to the companion diagnostic tests in oncology market demand.

Integration of Artificial Intelligence (AI) in Companion Diagnostics Augmenting Market Progress

Vendors operating in the companion diagnostic tests in oncology market landscape are investing in the R&D of AI-assisted diagnostics. AI is gaining traction in clinical diagnostics, with radiology and imaging being the early adopters of the technology.

Rise in investment in digital pathology and AI is projected to boost the market statistics during the forecast period. Digital pathology can improve workflows and increase efficacy for laboratory pathology. The integration of AI can further improve productivity and shorten turnaround time in pathology laboratories.

Major diagnostics service providers are incorporating AI algorithms in their digital pathology software. In October 2023, Roche partnered with Ibex Medical Analytics and Amazon Web Services to enable pathology laboratories to access Ibex’s AI-powered decision support tools to aid in the diagnosis of breast and prostate cancer.

Regional Outlook

Attribute Detail
Leading Region North America

As per the latest companion diagnostic tests in oncology market analysis, North America held largest share in 2023. Approval and launch of new products is fueling the market statistics in North America. In 2023, the U.S. FDA approved the FoundationOne CDx for use as a companion diagnostic to identify patients with advanced hormone receptor–positive, HER2-negative advanced breast cancer who may be eligible for treatment with the combination of capivasertib (Truqap) and fulvestrant (Faslodex).

Analysis of Key Players

Major companies in the companion diagnostic tests in oncology market are focusing on launching new products to expand their product portfolio. Abbott, F. Hoffmann-La Roche AG, Genomic Health, Inc., QIAGEN, Agilent Technologies, Inc., AGENDIA N.V., bioMérieux SA, Illumina, Inc., Siemens Healthineers, Thermo Fisher Scientific Inc., and BioGenex are key players operating in the companion diagnostic tests in oncology industry.

These companies have been profiled in the companion diagnostic tests in oncology market report based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.

Key Developments

  • In December 2022, QIAGEN received the U.S. FDA approval for its therascreen KRAS RGQ PCR kit (therascreen KRAS kit) as a companion diagnostic test to Mirati Therapeutic’s drug KRAZATI (adagrasib) for non-small cell lung cancer (NSCLC).
  • In July 2021, Labcorp announced the availability of therascreen KRAS PCR Mutation Analysis, a companion diagnostic to identify patients with non-small cell lung cancer (NSCLC) who are eligible for treatment with LUMAKRAS (sotorasib), a new treatment option developed by Amgen

Companion Diagnostic Tests in Oncology Market Snapshot

Attribute Detail
Market Size in 2023 US$ 6.1 Bn
Market Forecast (Value) in 2034 US$ 17.0 Bn
Growth Rate (CAGR) 9.5%
Forecast Period 2024-2034
Historical Data Available for 2020-2022
Quantitative Units US$ Bn for Value
Market Analysis It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.
Competition Landscape
  • Market share analysis by company (2023)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format Electronic (PDF) + Excel
Market Segmentation
  • By Detection Technique
  • By Biomarker
    • EGFR
    • KRAS
    • HER2
    • BRAF V600E
    • Others
  • By Cancer Type
    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Liver Cancer
    • Melanoma
    • Others
  • By End-user
    • Hospitals
    • Specialty Clinics
    • Diagnostic Labs
    • Others
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • South Africa
  • GCC
Companies Profiled
  • Abbott
  • F. Hoffmann-LA Roche AG
  • Genomic Health, Inc.
  • QIAGEN
  • Agilent Technologies, Inc.
  • AGENDIA N.V.
  • bioMérieux SA
  • Illumina, Inc.
  • Siemens Healthineers
  • Thermo Fisher Scientific Inc.
  • BioGenex
Customization Scope Available Upon Request
Pricing Available Upon Request


 

Frequently Asked Questions

How big was the global companion diagnostic tests in oncology market in 2023?

It was valued at US$ 6.1 Bn in 2023

How is the companion diagnostic tests in oncology business expected to grow during the forecast period?

It is projected to grow at a CAGR of 9.5% from 2024 to 2034

What are the key factors driving the demand for companion diagnostic tests in oncology?

Increase in demand for targeted medicines and integration of artificial intelligence (AI) in companion diagnostics

Which region dominated the companion diagnostic tests in oncology landscape in 2023?

North America was the dominant region in 2023

Who are the key manufacturers of companion diagnostic tests in oncology?

Abbott, F. Hoffmann-La Roche AG, Genomic Health, Inc., QIAGEN, Agilent Technologies, Inc., AGENDIA N.V., bioMérieux SA, Illumina, Inc., Siemens Healthineers, Thermo Fisher Scientific Inc., and BioGenex

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Companion Diagnostic Tests in Oncology Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Product Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, 2020 - 2034

    5. Key Insights

        5.1. Pipeline Analysis

        5.2. Key Product/Brand Analysis

        5.3. Key Mergers & Acquisitions

        5.4. COVID-19 Pandemic Impact on Industry

    6. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by Detection Technique

        6.1. Introduction and Definitions

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Detection Technique, 2020 - 2034

            6.3.1. Protein Detection

                6.3.1.1. Immunohistochemistry

            6.3.2. DNA Detection

                6.3.2.1. Polymerase Chain Reaction (PCR)

                6.3.2.2. Next-generation Sequencing (NGS)

                6.3.2.3. In Situ Hybridization

            6.3.3. Others

        6.4. Market Attractiveness, by Detection Technique

    7. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by Biomarker

        7.1. Introduction and Definitions

        7.2. Key Findings/Developments

        7.3. Market Value Forecast, by Biomarker, 2020 - 2034

            7.3.1. EGFR

            7.3.2. KRAS

            7.3.3. HER2

            7.3.4. BRAF V600E

            7.3.5. Others

            7.3.6. 7.4 Market Attractiveness, by Biomarker

    8. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by Cancer Type

        8.1. Introduction and Definitions

        8.2. Key Findings/Developments

        8.3. Market Value Forecast, by Cancer Type, 2020 - 2034

            8.3.1. Breast Cancer

            8.3.2. Lung Cancer

            8.3.3. Colorectal Cancer

            8.3.4. Liver Cancer

            8.3.5. Melanoma

            8.3.6. Others

        8.4. Market Attractiveness, by Cancer Type

    9. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by End-user

        9.1. Introduction and Definitions

        9.2. Key Findings/Developments

        9.3. Market Value Forecast, by End-user, 2020 - 2034

            9.3.1. Hospitals

            9.3.2. Specialty Clinics

            9.3.3. Diagnostic Labs

            9.3.4. Others

        9.4. Market Attractiveness, by End-user

    10. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by Region

        10.1. Key Findings

        10.2. Market Value Forecast, by Region, 2020 - 2034

            10.2.1. North America

            10.2.2. Europe

            10.2.3. Asia Pacific

            10.2.4. Latin America

            10.2.5. Middle East & Africa

        10.3. Market Attractiveness, by Region

    11. North America Companion Diagnostic Tests in Oncology Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Detection Technique, 2020 - 2034

            11.2.1. Protein Detection

                11.2.1.1. Immunohistochemistry

            11.2.2. DNA Detection

                11.2.2.1. Polymerase Chain Reaction (PCR)

                11.2.2.2. Next-generation Sequencing (NGS)

                11.2.2.3. In Situ Hybridization

            11.2.3. Others

        11.3. Market Attractiveness, by Detection Technique

        11.4. Market Value Forecast, by Biomarker, 2020 - 2034

            11.4.1. EGFR

            11.4.2. KRAS

            11.4.3. HER2

            11.4.4. BRAF V600E

            11.4.5. Others

        11.5. Market Attractiveness, by Biomarker

        11.6. Market Value Forecast, by Cancer Type, 2020 - 2034

            11.6.1. Breast Cancer

            11.6.2. Lung Cancer

            11.6.3. Colorectal Cancer

            11.6.4. Liver Cancer

            11.6.5. Melanoma

            11.6.6. Others

        11.7. Market Attractiveness, by Cancer Type

        11.8. Market Value Forecast, by End-user, 2020 - 2034

            11.8.1. Hospitals

            11.8.2. Specialty Clinics

            11.8.3. Diagnostic Labs

            11.8.4. Others

        11.9. Market Attractiveness, by End-user

        11.10. Market Value Forecast, by Country, 2020 - 2034

            11.10.1. U.S.

            11.10.2. Canada

        11.11. Market Attractiveness Analysis

            11.11.1. By Detection Technique

            11.11.2. By Biomarker

            11.11.3. By Cancer Type

            11.11.4. By End-user

            11.11.5. By Country

    12. Europe Companion Diagnostic Tests in Oncology Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Detection Technique, 2020 - 2034

            12.2.1. Protein Detection

                12.2.1.1. Immunohistochemistry

            12.2.2. DNA Detection

                12.2.2.1. Polymerase Chain Reaction (PCR)

                12.2.2.2. Next-generation Sequencing (NGS)

                12.2.2.3. In Situ Hybridization

            12.2.3. Others

        12.3. Market Attractiveness, by Detection Technique

        12.4. Market Value Forecast, by Biomarker, 2020 - 2034

            12.4.1. EGFR

            12.4.2. KRAS

            12.4.3. HER2

            12.4.4. BRAF V600E

            12.4.5. Others

        12.5. Market Attractiveness, by Biomarker

        12.6. Market Value Forecast, by Cancer Type, 2020 - 2034

            12.6.1. Breast Cancer

            12.6.2. Lung Cancer

            12.6.3. Colorectal Cancer

            12.6.4. Liver Cancer

            12.6.5. Melanoma

            12.6.6. Others

        12.7. Market Attractiveness, by Cancer Type

        12.8. Market Value Forecast, by End-user, 2020 - 2034

            12.8.1. Hospitals

            12.8.2. Specialty Clinics

            12.8.3. Diagnostic Labs

            12.8.4. Others

        12.9. Market Attractiveness, by End-user

        12.10. Market Value Forecast, by Country/Sub-region, 2020 - 2034

            12.10.1. Germany

            12.10.2. U.K.

            12.10.3. France

            12.10.4. Italy

            12.10.5. Spain

            12.10.6. Rest of Europe

        12.11. Market Attractiveness Analysis

            12.11.1. By Detection Technique

            12.11.2. By Biomarker

            12.11.3. By Cancer Type

            12.11.4. By End-user

            12.11.5. By Country/Sub-region

    13. Asia Pacific Companion Diagnostic Tests in Oncology Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Detection Technique, 2020 - 2034

            13.2.1. Protein Detection

                13.2.1.1. Immunohistochemistry

            13.2.2. DNA Detection

                13.2.2.1. Polymerase Chain Reaction (PCR)

                13.2.2.2. Next-generation Sequencing (NGS)

                13.2.2.3. In Situ Hybridization

            13.2.3. Others

        13.3. Market Attractiveness, by Detection Technique

        13.4. Market Value Forecast, by Biomarker, 2020 - 2034

            13.4.1. EGFR

            13.4.2. KRAS

            13.4.3. HER2

            13.4.4. BRAF V600E

            13.4.5. Others

        13.5. Market Attractiveness, by Biomarker

        13.6. Market Value Forecast, by Cancer Type, 2020 - 2034

            13.6.1. Breast Cancer

            13.6.2. Lung Cancer

            13.6.3. Colorectal Cancer

            13.6.4. Liver Cancer

            13.6.5. Melanoma

            13.6.6. Others

        13.7. Market Attractiveness, by Cancer Type

        13.8. Market Value Forecast, by End-user, 2020 - 2034

            13.8.1. Hospitals

            13.8.2. Specialty Clinics

            13.8.3. Diagnostic Labs

            13.8.4. Others

        13.9. Market Attractiveness, by End-user

        13.10. Market Value Forecast, by Country/Sub-region, 2020 - 2034

            13.10.1. China

            13.10.2. Japan

            13.10.3. India

            13.10.4. Australia & New Zealand

            13.10.5. Rest of Asia Pacific

        13.11. Market Attractiveness Analysis

            13.11.1. By Detection Technique

            13.11.2. By Biomarker

            13.11.3. By Cancer Type

            13.11.4. By End-user

            13.11.5. By Country/Sub-region

    14. Latin America Companion Diagnostic Tests in Oncology Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Detection Technique, 2020 - 2034

            14.2.1. Protein Detection

                14.2.1.1. Immunohistochemistry

            14.2.2. DNA Detection

                14.2.2.1. Polymerase Chain Reaction (PCR)

                14.2.2.2. Next-generation Sequencing (NGS)

                14.2.2.3. In Situ Hybridization

            14.2.3. Others

        14.3. Market Attractiveness, by Detection Technique

        14.4. Market Value Forecast, by Biomarker, 2020 - 2034

            14.4.1. EGFR

            14.4.2. KRAS

            14.4.3. HER2

            14.4.4. BRAF V600E

            14.4.5. Others

        14.5. Market Attractiveness, by Biomarker

        14.6. Market Value Forecast, by Cancer Type, 2020 - 2034

            14.6.1. Breast Cancer

            14.6.2. Lung Cancer

            14.6.3. Colorectal Cancer

            14.6.4. Liver Cancer

            14.6.5. Melanoma

            14.6.6. Others

        14.7. Market Attractiveness, by Cancer Type

        14.8. Market Value Forecast, by End-user, 2020 - 2034

            14.8.1. Hospitals

            14.8.2. Specialty Clinics

            14.8.3. Diagnostic Labs

            14.8.4. Others

        14.9. Market Attractiveness, by End-user

        14.10. Market Value Forecast, by Country/Sub-region, 2020 - 2034

            14.10.1. Brazil

            14.10.2. Mexico

            14.10.3. Rest of Latin America

        14.11. Market Attractiveness Analysis

            14.11.1. By Detection Technique

            14.11.2. By Biomarker

            14.11.3. By Cancer Type

            14.11.4. By End-user

            14.11.5. By Country/Sub-region

    15. Middle East & Africa Companion Diagnostic Tests in Oncology Market Analysis and Forecast

        15.1. Introduction

            15.1.1. Key Findings

        15.2. Market Value Forecast, by Detection Technique, 2020 - 2034

            15.2.1. Protein Detection

                15.2.1.1. Immunohistochemistry

            15.2.2. DNA Detection

                15.2.2.1. Polymerase Chain Reaction (PCR)

                15.2.2.2. Next-generation Sequencing (NGS)

                15.2.2.3. In Situ Hybridization

            15.2.3. Others

        15.3. Market Attractiveness, by Detection Technique

        15.4. Market Value Forecast, by Biomarker, 2020 - 2034

            15.4.1. EGFR

            15.4.2. KRAS

            15.4.3. HER2

            15.4.4. BRAF V600E

            15.4.5. Others

        15.5. Market Attractiveness, by Biomarker

        15.6. Market Value Forecast, by Cancer Type, 2020 - 2034

            15.6.1. Breast Cancer

            15.6.2. Lung Cancer

            15.6.3. Colorectal Cancer

            15.6.4. Liver Cancer

            15.6.5. Melanoma

            15.6.6. Others

        15.7. Market Attractiveness, by Cancer Type

        15.8. Market Value Forecast, by End-user, 2020 - 2034

            15.8.1. Hospitals

            15.8.2. Specialty Clinics

            15.8.3. Diagnostic Labs

            15.8.4. Others

        15.9. Market Attractiveness, by End-user

        15.10. Market Value Forecast, by Country/Sub-region, 2020 - 2034

            15.10.1. GCC Countries

            15.10.2. South Africa

            15.10.3. Rest of Middle East & Africa

        15.11. Market Attractiveness Analysis

            15.11.1. By Detection Technique

            15.11.2. By Biomarker

            15.11.3. By Cancer Type

            15.11.4. By End-user

            15.11.5. By Country/Sub-region

    16. Competition Landscape

        16.1. Market Player – Competition Matrix (By Tier and Size of Companies)

        16.2. Market Share Analysis, by Company (2023)

        16.3. Company Profiles

            16.3.1. Abbott

                16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.1.2. Product Portfolio

                16.3.1.3. Financial Overview

                16.3.1.4. SWOT Analysis

                16.3.1.5. Strategic Overview

            16.3.2. F. Hoffmann-LA Roche AG

                16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.2.2. Product Portfolio

                16.3.2.3. Financial Overview

                16.3.2.4. SWOT Analysis

                16.3.2.5. Strategic Overview

            16.3.3. Genomic Health, Inc.

                16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.3.2. Product Portfolio

                16.3.3.3. Financial Overview

                16.3.3.4. SWOT Analysis

                16.3.3.5. Strategic Overview

            16.3.4. QIAGEN

                16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.4.2. Product Portfolio

                16.3.4.3. Financial Overview

                16.3.4.4. SWOT Analysis

                16.3.4.5. Strategic Overview

            16.3.5. Agilent Technologies, Inc.

                16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.5.2. Product Portfolio

                16.3.5.3. Financial Overview

                16.3.5.4. SWOT Analysis

                16.3.5.5. Strategic Overview

            16.3.6. AGENDIA N.V.

                16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.6.2. Product Portfolio

                16.3.6.3. Financial Overview

                16.3.6.4. SWOT Analysis

                16.3.6.5. Strategic Overview

            16.3.7. bioMérieux SA

                16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.7.2. Product Portfolio

                16.3.7.3. Financial Overview

                16.3.7.4. SWOT Analysis

                16.3.7.5. Strategic Overview

            16.3.8. Illumina, Inc.

                16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.8.2. Product Portfolio

                16.3.8.3. Financial Overview

                16.3.8.4. SWOT Analysis

                16.3.8.5. Strategic Overview

            16.3.9. Siemens Healthineers

                16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.9.2. Product Portfolio

                16.3.9.3. Financial Overview

                16.3.9.4. SWOT Analysis

                16.3.9.5. Strategic Overview

            16.3.10. Thermo Fisher Scientific Inc.

                16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.10.2. Product Portfolio

                16.3.10.3. Financial Overview

                16.3.10.4. SWOT Analysis

                16.3.10.5. Strategic Overview

            16.3.11. BioGenex

                16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.11.2. Product Portfolio

                16.3.11.3. Financial Overview

                16.3.11.4. SWOT Analysis

                16.3.11.5. Strategic Overview

    List of Tables

    Table 01: Global Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Detection Technique, 2020 - 2034

    Table 02: Global Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Biomarker, 2020 - 2034

    Table 03: Global Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by End-user, 2020 - 2034

    Table 04: Global Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Cancer Type, 2020 - 2034

    Table 05: Global Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Region, 2020 - 2034

    Table 06: North America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Country, 2020 - 2034

    Table 07: North America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Detection Technique, 2020 - 2034

    Table 08: North America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Biomarker, 2020 - 2034

    Table 9: North America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Cancer Type, 2020 - 2034

    Table 10: North America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by End-user, 2020 - 2034

    Table 11: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Country/Sub-region, 2020 - 2034

    Table 12: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Detection Technique, 2020 - 2034

    Table 13: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Biomarker, 2020 - 2034

    Table 14: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Cancer Type, 2020 - 2034

    Table 15: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by End-user, 2020 - 2034

    Table 16: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Country/Sub-region, 2020 - 2034

    Table 17: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Detection Technique, 2020 - 2034

    Table 18: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Biomarker, 2020 - 2034

    Table 19: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Cancer Type, 2020 - 2034

    Table 20: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by End-user, 2020 - 2034

    Table 21: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Country/Sub-region, 2020 - 2034

    Table 22: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Detection Technique, 2020 - 2034

    Table 23: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Biomarker, 2020 - 2034

    Table 24: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Cancer Type, 2020 - 2034

    Table 25: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by End-user, 2020 - 2034

    Table 26: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Country/Sub-region, 2020 - 2034

    Table 27: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Detection Technique, 2020 - 2034

    Table 28: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Biomarker, 2020 - 2034

    Table 29: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Cancer Type, 2020 - 2034

    Table 30: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by End-user, 2020 - 2034

    List of Figures

    Figure 01: Global Companion Diagnostic Tests in Oncology Market Size (US$ Million), by Region, 2023 - 2034

    Figure 02: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Million), by Detection Technique, 2023

    Figure 03: Global Companion Diagnostic Tests in Oncology Market Value Share, by Detection Technique, 2023

    Figure 04: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Million), by Biomarker, 2023

    Figure 05: Global Companion Diagnostic Tests in Oncology Market Value Share, by Biomarker, 2023

    Figure 06: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Million), by Cancer Type, 2023

    Figure 07: Global Companion Diagnostic Tests in Oncology Market Value Share, by Cancer Type, 2023

    Figure 08: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Million), by End-user, 2023

    Figure 09: Global Companion Diagnostic Tests in Oncology Market Value Share, by End-user, 2023

    Figure 10: Global Companion Diagnostic Tests in Oncology Market Value Share, by Region, 2023

    Figure 11: Global Companion Diagnostic Tests in Oncology Market Value (US$ Million) Forecast, 2020 - 2034

    Figure 12: Global Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Detection Technique, 2023 - 2034

    Figure 13: Global Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Detection Technique, 2024 - 2034

    Figure 14: Global Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Biomarker, 2023 - 2034

    Figure 15: Global Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Biomarker, 2024 - 2034

    Figure 16: Global Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Cancer Type, 2023 - 2034

    Figure 17: Global Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Cancer Type, 2024 - 2034

    Figure 18: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Million), by End-user, 2023

    Figure 19: Global Companion Diagnostic Tests in Oncology Market Value Share, by End-user, 2023

    Figure 20: Global Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Region, 2023 - 2034

    Figure 21: Global Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Region, 2024 - 2034

    Figure 22: North America Companion Diagnostic Tests in Oncology Market Value (US$ Million) Forecast and Y-o-Y Growth (%), 2020 - 2034

    Figure 23: North America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Country, 2024 - 2034

    Figure 24: North America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Country, 2023 - 2034

    Figure 25: North America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Detection Technique, 2023 - 2034

    Figure 26: North America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Biomarker, 2023 - 2034

    Figure 27: North America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Cancer Type, 2023 - 2034

    Figure 28: North America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by End-user, 2023 - 2034

    Figure 29: North America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Detection Technique, 2024 - 2034

    Figure 30: North America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Biomarker, 2024 - 2034

    Figure 31: North America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Cancer Type, 2024 - 2034

    Figure 32: North America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by End-user, 2024 - 2034

    Figure 33: Europe Companion Diagnostic Tests in Oncology Market Value (US$ Million) Forecast and Y-o-Y Growth (%), 2020 - 2034

    Figure 34: Europe Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Country/Sub-region, 2024 - 2034

    Figure 35: Europe Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Country/Sub-region, 2023 - 2034

    Figure 36: Europe Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Detection Technique, 2023 - 2034

    Figure 37: Europe Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Biomarker, 2023 - 2034

    Figure 38: Europe Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Cancer Type, 2023 - 2034

    Figure 39: Europe Companion Diagnostic Tests in Oncology Market Value Share Analysis, by End-user, 2023 - 2034

    Figure 40: Europe Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Detection Technique, 2024 - 2034

    Figure 41: Europe Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Biomarker, 2024 - 2034

    Figure 42: Europe Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Cancer Type, 2024 - 2034

    Figure 43: Europe Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by End-user, 2024 - 2034

    Figure 44: Asia Pacific Companion Diagnostic Tests in Oncology Market Value (US$ Million) Forecast and Y-o-Y Growth (%), 2020 - 2034

    Figure 45: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Country/Sub-region, 2024 - 2034

    Figure 46: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Country/Sub-region, 2023 - 2034

    Figure 47: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Detection Technique, 2023 - 2034

    Figure 48: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Biomarker, 2023 - 2034

    Figure 49: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Cancer Type, 2023 - 2034

    Figure 50: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share Analysis, by End-user, 2023 - 2034

    Figure 51: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Detection Technique, 2024 - 2034

    Figure 52: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Biomarker, 2024 - 2034

    Figure 53: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Cancer Type, 2024 - 2034

    Figure 54: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by End-user, 2023–2034

    Figure 55: Latin America Companion Diagnostic Tests in Oncology Market Value (US$ Million) Forecast and Y-o-Y Growth (%), 2020 - 2034

    Figure 56: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Country/Sub-region, 2024 - 2034

    Figure 57: Latin America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Country/Sub-region, 2023 - 2034

    Figure 58: Latin America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Detection Technique, 2023 - 2034

    Figure 59: Latin America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Biomarker, 2023 - 2034

    Figure 60: Latin America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Cancer Type, 2023 - 2034

    Figure 61: Latin America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by End-user, 2023 - 2034

    Figure 62: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Detection Technique, 2024 - 2034

    Figure 63: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Biomarker, 2024 - 2034

    Figure 64: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Cancer Type, 2024 - 2034

    Figure 65: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by End-user, 2024 - 2034

    Figure 66: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast and Y-o-Y Growth (%), 2020 - 2034

    Figure 67: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Country/Sub-region, 2024 - 2034

    Figure 68: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Country/Sub-region, 2023 - 2034

    Figure 69: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Detection Technique, 2023 - 2034

    Figure 70: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Biomarker, 2023 - 2034

    Figure 71: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Cancer Type, 2023 - 2034

    Figure 72: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by End-user, 2023 - 2034

    Figure 73: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Detection Technique, 2024 - 2034

    Figure 74: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Biomarker, 2024 - 2034

    Figure 75: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Cancer Type, 2024 - 2034

    Figure 76: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by End-user, 2024 - 2034

Copyright © Transparency Market Research, Inc. All Rights reserved